



IFW

Attorney Docket No. 25079-Y

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SENN-BILFINGER, Jörg
BUHR, Wilm

Serial No. 10/826,337

Examiner: Not yet assigned

Filed: April 19, 2004

Group Art Unit: Not yet assigned

Title: PRODRUGS OF IMAZOPYRIDINE DERIVATIVES

TRANSMITTAL LETTER

The Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter
- (2) Supplemental Information Disclosure Statement;
- (3) Form PTO-1449 citing seven (7) references; and
- (4) Copies of two (2) non-U.S. patent references.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By: _____


Gary M. Nath
Registration No. 26,965
Jerald L. Meyer
Registration No. 41,194
Sheldon M. McGee
Registration No. 50,454
Customer No. 34375

Date: August 23, 2004
NATH & ASSOCIATES PLLC
1030 15TH Street, NW - 6th Floor
Washington, D.C. 20005
GMN/SMM/DS2.TL



Attorney Docket No. 25079-Y

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SENN-BILFINGER, Jörg
BUHR, Wilm

Serial No. 10/826,337

Examiner: Not yet assigned

Filed: April 19, 2004

Group Art Unit: Not yet assigned

Title: PRODRUGS OF IMAZOPYRIDINE DERIVATIVES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. §1.97-1.98. Please note the following particulars:

[NOTE: Only one of items a, b, c, and d must be checked.]

- a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. §1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311.

The enclosed statement is accompanied by [check one]:

- i. a certification in part (e) below as specified in 37 C.F.R. §1.97(e), or
 ii. a check in the amount required by 37 C.F.R. §1.17(p).

- c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311, but before payment of the issue fee.

Certification report(e) below; and
 a check in the amount as required by §1.17(p).

- d. The enclosed statement is being filed pursuant to
37 C.F.R. §1.97(i), for placement in the file.

- e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

- [] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,
or
- [] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- or
- [] Appropriate certification is attached.

- [x] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.
- [x] g. Copies of the non-U.S. patent documents are attached herewith with a completed Form PTO-1449.

OR


- [] Copies of the documents are not attached as allowed under CFR 1.98(d)(1).

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.


If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By:


Gary M. Nath
Registration No. 26,965
Jerald L. Meyer
Registration No. 41,194
Sheldon M. McGee
Registration No. 50,454
Customer No. 34375

Date: August 23, 2004
NATH & ASSOCIATES PLLC
1030 15TH Street, NW - 6th Floor
Washington, D.C. 20005
GMN/SMM/DS2.



FORM PTO-1449

INFORMATION DISCLOSURE CITATIONAtty Docket
25079YSerial No.
10/826,337Applicant
SENN-BILFINGER, et al.Filing Date
April 19, 2004Group Art Unit
Not yet assigned

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
	AA	4,673,679	6/16/1987	Augnst, et al.	514	282	5/14/1986
	AB	5,432,183	7/11/1995	Schulte	514	291	11/30/1993
	AC	6,160,119	12/12/2000	Senn-Bilfinger	543	83	11/16/1999
	AD	6,197,783	3/6/2000	Senn-Bilfinger, et al.	514	293	9/24/1999
	AE	6,436,953	8/20/2002	Senn-Bilfinger	514	293	7/19/2000
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Trans-lation
	AL	WO 01/072754	10/4/2001	WO			N/A
	AM						
	AN						
	AO						
	AP						

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR		Bundgaard, H., <u>Design of Prodrugs</u> , Elsevier Science, pgs. 1-3 (1985).
AS		
AT		
AU		
AV		

Examiner	
----------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.
 Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to Applicant.